GLP-1s drive rebound in snacking category M&A, analysis finds

Babybel 2 pack

The popularisation of GLP-1 weight-loss drugs has driven a rebound in M&A in snacking companies around the world, according to analysis by investment bank Houlihan Lokey

The popularisation of GLP-1 weight-loss drugs has driven a rebound in M&A in snacking companies around the world, according to analysis by investment bank Houlihan Lokey.

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW